Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience
Open Access
- 7 July 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (17) , 6093-6101
Abstract
Purpose: The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinoblastoma, and hinders the confirmation of somatic RB1 mutations necessary for genetic counseling. Plasma cell‐free DNA (cfDNA) has provided a platform for noninvasive molecular profiling in cancer, but its applicability in low tumor burden retinoblastoma has not been shown. We analyzed cfDNA collected from 10 patients with available tumor tissue to determine whether sufficient tumorderived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive RB1 mutation detection.Methods: Tumor tissue was collected from eye enucleations in 10 patients diagnosed with advanced intra‐ocular unilateral retinoblastoma, three of which went on to develop metastatic disease. Tumor RB1 mutation status was determined using an FDA‐cleared tumor sequencing assay, MSK‐IMPACT. Plasma samples were collected before eye enucleation and analyzed with a customized panel targeting all exons of RB1.Results: Tumor‐guided genotyping detected 10 of the 13 expected somatic RB1 mutations in plasma cfDNA in 8 of 10 patients (average variant allele frequency 3.78%). Without referring to RB1 status in the tumor, de novo mutation calling identified 7 of the 13 expected RB1 mutations (in 6 of 10 patients) with high confidence.Conclusion: Plasma cfDNA can detect somatic RB1 mutations in patients with unilateral retinoblastoma. Since intraocular biopsies are avoided in these patients because of concern about spreading tumor, cfDNA can potentially offer a noninvasive platform to guide clinical decisions about treatment, follow‐up schemes, and risk of metastasis.Keywords
Funding Information
- National Cancer Institute (P30 CA008748)
This publication has 40 references indexed in Scilit:
- Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCCPLOS ONE, 2015
- The Biology of Retinoblastoma2015
- Retinoblastoma: Saving Life with VisionAnnual Review of Medicine, 2014
- Spectrum of RB1 mutations identified in 403 retinoblastoma patientsJournal of Medical Genetics, 2013
- The genomic landscape of retinoblastoma: a reviewClinical & Experimental Ophthalmology, 2013
- Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studiesThe Lancet Oncology, 2013
- RetinoblastomaThe Lancet, 2012
- Incidence of retinoblastoma in the USA: 1975-2004British Journal of Ophthalmology, 2008
- Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutationEuropean Journal of Cancer, 2006
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971